Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Chen, AC; Migliaccio, I; Rimawi, M; Lopez-Tarruella, S; Creighton, CJ; Massarweh, S; Huang, C; Wang, YC; Batra, SK; Gutierrez, MC; Osborne, CK; Schiff, R.

Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies

BREAST CANCER RESEARCH AND TREATMENT. 2012; 134(2): 583-593 Nº de citas: 27 [doi:10.1007/s10549-012-2082-9]

Virizuela, JA; Escobar, Y; Cassinello, J; Borrega, P.

Treatment of cancer pain: Spanish Society of Medical Oncology (SEOM) recommendations for clinical practice

CLINICAL & TRANSLATIONAL ONCOLOGY. 2012; 14(7): 499-504 Nº de citas: 23 [doi:10.1007/s12094-012-0831-1]

Hurvitz, SA; Betting, DJ; Stem, HM; Quinaux, E; Stinson, J; Seshagiri, S; Zhao, Y; Buyse, M; Mackey, J; Driga, A; Damaraju, S; Sliwkowski, MX; Robert, NJ; Valero, V; Crown, J; Falkson, C; Brufsky, A; Pienkowski, T; Eiermann, W; Martin, M; Bee, V; Marathe, O; Slamon, DJ; Timmerman, JM.

Analysis of Fc gamma Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients

CLINICAL CANCER RESEARCH. 2012; 18(12): 3478-3486 Nº de citas: 103 [doi:10.1158/1078-0432.CCR-11-2294]

Lopez-Tarruella, S; Jerez, Y; Marquez-Rodas, I; Martin, M.

Neratinib (HKI-272) in the treatment of breast cancer

Future Oncology. 2012; 8(6): 671-681 Nº de citas: 23 [doi:10.2217/FON.12.66]

Guisado-Vasco, P; Arranz-Saez, R; Canales, M; Canovas, A; Garcia-Larana, J; Garcia-Sanz, R; Lopez, A; Lopez, JL; Llanos, M; Moraleda, JM; Rodriguez, J; Rayon, C; Sabin, P; Salar, A; Marin-Niebla, A; Morente, M; Sanchez-Godoy, P; Tomas, JF; Muriel, A; Abraira, V; Piris, MA; Garcia, JF; Montalban, C.

Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series

LEUKEMIA & LYMPHOMA. 2012; 53(5): 812-819 Nº de citas: 15 [doi:10.3109/10428194.2011.635861]

Gutierrez, LC; Khosravi-Shahi, P; Alvarez, YE.

Management of dermatitis in patients with locally advanced squamous cell carcinoma of the head and neck receiving cetuximab and radiotherapy

ORAL ONCOLOGY. 2012; 48(4): 293-297 Nº de citas: 18 [doi:10.1016/j.oraloncology.2011.10.019]

Martin, M; Makhson, A; Gligorov, J; Lichinitser, M; Lluch, A; Semiglazov, V; Scotto, N; Mitchell, L; Tjulandin, S.

Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer

ONCOLOGIST. 2012; 17(4): 469-475 Nº de citas: 38 [doi:10.1634/theoncologist.2011-0344]

Miles, D; Zielinski, C; Martin, M; Vrdoljak, E; Robert, N.

Combining capecitabine and bevacizumab in metastatic breast cancer: A comprehensive review

EUROPEAN JOURNAL OF CANCER. 2012; 48(4): 482-491 Nº de citas: 16 [doi:10.1016/j.ejca.2011.12.007]

Rosell, R; Carcereny, E; Gervais, R; Vergnenegre, A; Massuti, B; Felip, E; Palmero, R; Garcia-Gomez, R; Pallares, C; Sanchez, JM; Porta, R; Cobo, M; Garrido, P; Longo, F; Moran, T; Insa, A; De Marinis, F; Corre, R; Bover, I; Illiano, A; Dansin, E; de Castro, J; Milella, M; Reguart, N; Altavilla, G; Jimenez, U; Provencio, M; Moreno, MA; Terrasa, J; Munoz-Langa, J; Valdivia, J; Isla, D; Domine, M; Molinier, O; Mazieres, J; Baize, N; Garcia-Campelo, R; Robinet, G; Rodriguez-Abreu, D; Lopez-Vivanco, G; Gebbia, V; Ferrera-Delgado, L; Bombaron, P; Bernabe, R; Bearz, A; Artal, A; Cortesi, E; Rolfo, C; Sanchez-Ronco, M; Drozdowskyj, A; Queralt, C; de Aguirre, I; Ramirez, JL; Sanchez, JJ; Molina, MA; Taron, M; Paz-Ares, L.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

LANCET ONCOLOGY. 2012; 13(3): 239-246 Nº de citas: 4909 [doi:10.1016/S1470-2045(11)70393-X]

Albanell, J; Gonzalez, A; Ruiz-Borrego, M; Alba, E; Garcia-Saenz, JA; Corominas, JM; Burgues, O; Furio, V; Rojo, A; Palacios, J; Bermejo, B; Martinez-Garcia, M; Limon, ML; Munoz, AS; Martin, M; Tusquets, I; Rojo, F; Colomer, R; Faull, I; Lluch, A.

Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER plus ) node-negative breast cancer

ANNALS OF ONCOLOGY. 2012; 23(3): 625-631 Nº de citas: 104 [doi:10.1093/annonc/mdr278]

Romero, A; Caldes, T; Diaz-Rubio, E; Martin, M.

Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?

CLINICAL & TRANSLATIONAL ONCOLOGY. 2012; 14(3): 163-168 Nº de citas: 22 [doi:10.1007/s12094-012-0779-1]

Eiermann, W; Bergh, J; Cardoso, F; Conte, P; Crown, J; Curtin, NJ; Gligorov, J; Gusterson, B; Joensuu, H; Linderholm, BK; Martin, M; Penault-Llorca, F; Pestalozzi, BC; Razis, E; Sotiriou, C; Tjulandin, S; Viale, G.

Triple negative breast cancer: Proposals for a pragmatic definition and implications for patient management and trial design

BREAST. 2012; 21(1): 20-26 Nº de citas: 24 [doi:10.1016/j.breast.2011.09.006]

Llombart-Cussac, A; Ruiz, A; Anton, A; Barnadas, A; Antolin, S; Ales-Martinez, JE; Alvarez, I; Andres, R; Saenz, JAG; Lao, J; Carrasco, E; Camara, C; Casas, I; Martin, M.

Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer Final Results from the Spanish Breast Cancer Group 2001-03 Phase 2 Randomized Trial

CANCER. 2012; 118(1): 241-247 Nº de citas: 21 [doi:10.1002/cncr.26299]

Marquez-Rodas, I; Lopez-Trabada, D; Blanco, ABR; Cabello, SC; Gomez, MIP; Clemente, MO; Calvo, FA; Martin, M.

Family History Record and Hereditary Cancer Risk Perception according to National Cancer Institute Criteria in a Spanish Medical Oncology Service: A Retrospective Study

ONCOLOGY. 2012; 82(1): 30-34 Nº de citas: 6 [doi:10.1159/000335960]

Sorensen, SV; Goh, JW; Pan, F; Chen, C; Yardley, D; Martin, M; Knopf, K; Benedict, A; Giorgetti, C; Iyer, S.

INCIDENCE-BASED COST-OF-ILLNESS MODEL FOR METASTATIC BREAST CANCER IN THE UNITED STATES

INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE. 2012; 28(1): 12-21 Nº de citas: 63 [doi:10.1017/S026646231100064X]

Arija, JAA; Beca, RG; Lopez, CL; Dominguez, PS; Lovelle, AS; Gilarranz, YJ.

Treatment of the patient with castration-resistant biochemical progression of prostate cancer

ARCHIVOS ESPANOLES DE UROLOGIA. 2012; 65(1): 185-192 Nº de citas: 1

Martin, M; Sanchez-Rovira, P; Munoz, M; Baena-Canada, JM; Mel, JR; Margeli, M; Ramos, M; Martinez, E; Garcia-Saenz, JA; Casado, A; Jaen, AM; Gonzalez-Farre, X; Escudero, MJ; Rodriguez-Martin, C; Carrasco, E.

Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study

ANNALS OF ONCOLOGY. 2011; 22(12): 2591-2596 Nº de citas: 28 [doi:10.1093/annonc/mdr024]

Alvarez, RH; Guarneri, V; Icli, F; Johnston, S; Khayat, D; Loibl, S; Martin, M; Zielinski, C; Conte, P; Hortobagyi, GN.

Bevacizumab Treatment for Advanced Breast Cancer

ONCOLOGIST. 2011; 16(12): 1684-1697 Nº de citas: 18 [doi:10.1634/theoncologist.2011-0113]